As part of PATH’s work in vaccine and pharmaceutical delivery technologies, this poster presents results from a user-acceptability study of two microarray patches (MAPs) in South Africa. The MAPs under assessment were designed for the self-administration of antiretrovirals, such as rilpilvirine, and may someday offer a discreet and effective form of PrEP protection for women at risk of HIV.
Corporate author(s): PATH
Publication date: May 2016
1,554 KB PDF
Hard copies are not available.
Some digital files may be saved at low resolutions to conserve file size. Versions with higher quality may be available; see the contact information below to enquire.
Related regions: Global
- Emerging and epidemic diseases > Drug development > HIV and AIDS
- Health technologies > Vaccine delivery
- Reproductive health > Sexually transmitted infections
For more information…
Contact: PATH Publications
Mailing address: PATH, PO Box 900922, Seattle, WA 98109 USA